Advanced glycation endproducts in diabetes-related macrovascular complications: focus on methylglyoxal

Diabetes is associated with vascular injury and the onset of macrovascular complications. Advanced glycation endproducts (AGEs) and the AGE precursor methylglyoxal (MGO) have been identified as key players in establishing the relationship between diabetes and vascular injury. While most research has focused on the link between AGEs and vascular injury, less is known about the effects of MGO on vasculature. In this review, we focus on the mechanisms linking AGEs and MGO to the development of atherosclerosis. AGEs and MGO are involved in many stages of atherosclerosis progression. However, more research is needed to determine the exact mechanisms underlying these effects. Nevertheless, AGEs and MGO could represent valid therapeutic targets for the macrovascular complications of diabetes.

Automated summary

Diabetes is linked to vascular injury and the development of macrovascular complications. Advanced glycation endproducts (AGEs) and the precursor methylglyoxal (MGO) play important roles in connecting diabetes and vascular injury. While most studies have focused on the relationship between AGEs and vascular injury, the effects of MGO on vasculature are less understood. This review explores the mechanisms linking AGEs and MGO to the progression of atherosclerosis. AGEs and MGO are involved in various stages of atherosclerosis, but further research is needed to understand the exact underlying mechanisms. Nonetheless, targeting AGEs and MGO could provide therapeutic strategies for the macrovascular complications of diabetes.